Max Healthcare

Is Max Healthcare overvalued or undervalued?

As of October 29, 2021, Max Healthcare Institute Ltd. is considered very expensive with a PE ratio of 100.29, significantly higher than its peers, indicating it may be overvalued despite a 43% return over the past year compared to the Sensex's 7.55%.

As of 29 October 2021, the valuation grade for Max Healthcare Institute Ltd. moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE Ratio of 100.29, a Price to Book Value of 12.11, and an EV to EBITDA of 62.71. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Max Healthcare's valuation appears steep, as it has a higher PE ratio than many competitors in the healthcare sector. For instance, while Max Healthcare's PE stands at 100.29, other industry players typically exhibit lower ratios, indicating that investors may be paying a high price for expected growth that may not materialize. Notably, the company's stock has outperformed the Sensex over the past year, with a return of 43% compared to the Sensex's 7.55%, which may have contributed to the inflated valuation.

Who are in the management team of Max Healthcare?

As of March 2023, the management team of Max Healthcare includes Chairman Abhay Soi, along with several non-executive and independent directors: Anil Bhatnagar, K Narasimha Murthy, Mahendra Lodha, Michael Thomas Neeb, Pranav Amin, Amrita Gangotra, and Narayan Seshadri.

As of March 2023, the management team of Max Healthcare includes the following individuals:<BR><BR>1. Abhay Soi - Chairman / Executive Director<BR>2. Anil Bhatnagar - Non-Executive & Non-Independent Director<BR>3. K Narasimha Murthy - Independent Non-Executive Director<BR>4. Mahendra Lodha - Independent Non-Executive Director<BR>5. Michael Thomas Neeb - Independent Non-Executive Director<BR>6. Pranav Amin - Independent Non-Executive Director<BR>7. Amrita Gangotra - Independent Non-Executive Director<BR>8. Narayan Seshadri - Non-Executive Director<BR><BR>These individuals play various roles within the company's governance structure.

Has Max Healthcare declared dividend?

Max Healthcare Institute Ltd has declared a 15% dividend, amounting to ₹1.5 per share, with an ex-date of August 23, 2024. The company has shown significant price appreciation over the years, particularly with a total return of 220.75% over three years.

Max Healthcare Institute Ltd has declared a 15% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 15%<BR>- Amount per share: 1.5<BR>- Ex-date: 23 Aug 24<BR><BR>Dividend Yield: 0.13%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was 6.09%, with a dividend return of 0%, resulting in a total return of 6.09%.<BR><BR>For the 1-year period, the price return was 40.24%, the dividend return was 0.19%, leading to a total return of 40.43%.<BR><BR>Over the 2-year period, the price return was 122.44%, with a dividend return of 0.42%, culminating in a total return of 122.86%.<BR><BR>In the 3-year period, the price return reached 220.06%, while the dividend return was 0.69%, resulting in a total return of 220.75%.<BR><BR>For the 4-year period, the price return was 373.32%, with a dividend return of 0.98%, leading to a total return of 374.3%.<BR><BR>In the 5-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>Overall, Max Healthcare has declared a dividend, which contributes to its total returns, particularly noticeable over longer periods. The company shows strong price appreciation, especially in the 3 to 4-year periods, despite lower dividend contributions.

Who are the peers of the Max Healthcare?

Max Healthcare's peers include Apollo Hospitals, Fortis Health, Narayana Hrudaya, Global Health, Aster DM Health, Krishna Institute, Rainbow Child, Dr. Agarwal's Health, and Jupiter Life Line. Among these, Max Healthcare and Apollo Hospitals show excellent growth and management risk, while Krishna Institute has the highest 1-year return at 85.24%.

Peers: Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Global Health, Aster DM Health., Krishna Institu., Rainbow Child., Dr Agarwal's Hea, Jupiter Life Lin.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, Krishna Institu., Rainbow Child., Dr Agarwal's Hea, and Jupiter Life Lin, while Average management risk is found at Fortis Health. and Aster DM Health. Growth is excellent at Max Healthcare and Apollo Hospitals, good at Fortis Health., Narayana Hrudaya, Dr Agarwal's Hea, and Jupiter Life Lin, while below average growth is noted at Aster DM Health., Krishna Institu., and Rainbow Child. Capital structure is excellent at Max Healthcare, Global Health, Krishna Institu., and Jupiter Life Lin, average at Apollo Hospitals, and good at Fortis Health., Narayana Hrudaya, Dr Agarwal's Hea, and Rainbow Child., while below average is seen at Aster DM Health.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Krishna Institu. at 85.24%, while the lowest is Dr Agarwal's Hea with no available data. Max Healthcare's 1-year return of 50.36% is significantly higher than Apollo Hospitals' 16.20% but lower than Krishna Institu.'s. Additionally, Aster DM Health. and Dr Agarwal's Hea have negative six-month returns.

What does Max Healthcare do?

Max Healthcare Institute Ltd is a large-cap hospital company in India, reporting net sales of ₹19,097 Cr and a net profit of ₹3,190 Cr for March 2025. It has a market capitalization of ₹123,419 Cr and key financial metrics include a P/E ratio of 109.00 and a return on equity of 12.08%.

Overview:<BR>Max Healthcare Institute Ltd operates in the hospital industry and is categorized as a large-cap company.<BR><BR>History:<BR>The company was originally incorporated as "Infinitum Technologies Private Limited" in New Delhi, India, on June 18, 2001. It changed its name to "Max Healthcare Institute Private Limited" following a Fresh Certificate of Incorporation dated June 28, 2002. The latest quarterly results reported are for March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 19,097 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 3,190 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 123,419 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 109.00 <BR>Industry P/E: 59 <BR>Dividend Yield: 0.24% <BR>Debt Equity: 0.25 <BR>Return on Equity: 12.08% <BR>Price to Book: 13.03 <BR><BR>Contact Details:<BR>Address: Not available <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the top shareholders of the Max Healthcare?

The top shareholders of Max Healthcare include Abhay Soi with 23.73%, Foreign Institutional Investors holding 54.74%, and mutual funds with 13.38%. The Government of Singapore is the largest public shareholder at 5.69%, while individual investors own 3.31%, with no pledged promoter holdings.

The top shareholders of Max Healthcare include a mix of institutional and individual investors. The largest shareholder is Abhay Soi, who holds 23.73% of the company. Foreign Institutional Investors (FIIs) are significant shareholders as well, collectively holding 54.74% of the shares, represented by 1020 FIIs. Additionally, mutual funds have a presence with 13.38% held across 33 schemes. The Government of Singapore is the highest public shareholder, owning 5.69%. Individual investors collectively hold 3.31% of the shares. Notably, there are no pledged promoter holdings.

How big is Max Healthcare?

As of 24th July, Max Healthcare Institute Ltd has a market capitalization of 122,491.00 Cr, with recent Net Sales of 7028.46 Cr and a Net Profit of 1075.88 Cr. Shareholder's Funds are 9,380.87 Cr, and Total Assets are valued at 15,186.44 Cr.

As of 24th July, Max Healthcare Institute Ltd has a market capitalization of 122,491.00 Cr, categorizing it as a Large Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 7028.46 Cr and a Net Profit of 1075.88 Cr.<BR><BR>As of March 2025, the Shareholder's Funds amounted to 9,380.87 Cr, while the Total Assets were valued at 15,186.44 Cr.

How has been the historical performance of Max Healthcare?

Max Healthcare has experienced substantial growth from Mar'20 to Mar'25, with net sales increasing from 1,059.03 Cr to 7,028.46 Cr, and profit after tax rising from 12.91 Cr to 1,075.88 Cr. Total assets grew from 3,973.66 Cr to 15,186.44 Cr, reflecting the company's successful expansion strategy.

Answer:<BR>Max Healthcare has shown significant growth in its historical performance, particularly in net sales, which increased from 1,059.03 Cr in Mar'20 to 7,028.46 Cr in Mar'25. This upward trend is reflected in total operating income, which also rose from 1,059.03 Cr in Mar'20 to 7,028.46 Cr in Mar'25. The total expenditure, excluding depreciation, grew from 965.45 Cr in Mar'20 to 5,179.66 Cr in Mar'25, indicating increased operational costs alongside revenue growth. Operating profit (PBDIT) has similarly improved, climbing from 141.66 Cr in Mar'20 to 2,004.44 Cr in Mar'25, while profit before tax increased from 12.78 Cr in Mar'20 to 1,406.37 Cr in Mar'25. The profit after tax also saw a rise, reaching 1,075.88 Cr in Mar'25 compared to 12.91 Cr in Mar'20. The company's earnings per share (EPS) increased from 1.1 in Mar'20 to 11.07 in Mar'25, showcasing enhanced profitability per share. On the balance sheet, total assets grew from 3,973.66 Cr in Mar'20 to 15,186.44 Cr in Mar'25, while total liabilities increased from 3,973.66 Cr to 2,488.83 Cr in the same period. Cash flow from operating activities improved significantly, reaching 1,459.00 Cr in Mar'25, although cash flow from investing activities showed a negative trend at -1,614.00 Cr.<BR><BR>Breakdown:<BR>Max Healthcare's financial performance has demonstrated remarkable growth over the years, particularly in net sales, which surged from 1,059.03 Cr in Mar'20 to 7,028.46 Cr in Mar'25. This growth in revenue is accompanied by a corresponding increase in total operating income, which reached 7,028.46 Cr in Mar'25, up from 1,059.03 Cr in Mar'20. The company's total expenditure also rose significantly, from 965.45 Cr in Mar'20 to 5,179.66 Cr in Mar'25, reflecting the costs associated with scaling operations. Operating profit (PBDIT) has shown a strong upward trajectory, increasing from 141.66 Cr in Mar'20 to 2,004.44 Cr in Mar'25, while profit before tax improved from 12.78 Cr to 1,406.37 Cr in the same period. The profit after tax reached 1,075.88 Cr in Mar'25, a substantial increase from 12.91 Cr in Mar'20. The earnings per share (EPS) also rose significantly, indicating improved profitability for shareholders. On the balance sheet, total assets expanded from 3,973.66 Cr to 15,186.44 Cr, while total liabilities increased from 3,973.66 Cr to 2,488.83 Cr, reflecting the company's growth strategy. Additionally, cash flow from operating activities improved to 1,459.00 Cr in Mar'25, despite a negative cash flow from investing activities of -1,614.00 Cr, indicating ongoing investments in growth.

Is Max Healthcare technically bullish or bearish?

As of December 4, 2025, Max Healthcare's trend has shifted to bearish with moderate strength, supported by bearish signals from the MACD, KST, and moving averages, despite some mixed signals on the monthly timeframe.

As of 4 December 2025, the technical trend for Max Healthcare has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include the weekly MACD and KST both showing bearish signals, along with daily moving averages confirming a bearish trend. The Bollinger Bands indicate a bearish outlook on the weekly timeframe, while the monthly indicators show a mix of mildly bearish and mildly bullish signals, suggesting some divergence. Overall, the bearish trend is reinforced by the recent price action, with a notable decline in the past week and month compared to the Sensex.

When is the next results date for Max Healthcare Institute Ltd?

The next results date for Max Healthcare Institute Ltd is 05 February 2026.

The next results date for Max Healthcare Institute Ltd is scheduled for 05 February 2026.

Are Max Healthcare Institute Ltd latest results good or bad?

Max Healthcare Institute Ltd's latest results show strong year-on-year growth with a net profit increase of 26.01% and revenue up 10.66%. However, sequential declines in profit and revenue, along with high valuation concerns, suggest a cautious outlook for investors.

Max Healthcare Institute Ltd's latest results present a mixed picture. On one hand, the company reported a net profit of ₹300.92 crore for Q3 FY26, which is a 26.01% increase year-on-year, indicating strong annual growth. Additionally, revenue rose by 10.66% year-on-year to ₹2,067.52 crore, reflecting the company's ability to capture growing healthcare demand.<BR><BR>However, the quarterly performance shows significant challenges. The net profit declined by 38.75% compared to the previous quarter, and revenue also saw a sequential decrease of 3.18%. This decline raises concerns about demand momentum and operational stability. Furthermore, the operating margin decreased to 26.04%, down 89 basis points from the previous quarter, and the profit after tax margin fell sharply to 14.55%, down from 23.01% in Q2 FY26.<BR><BR>The company's valuation remains high, trading at 72 times trailing earnings, which is above the hospital sector average of 57 times. This premium valuation, combined with the recent operational headwinds and declining margins, raises questions about whether the current stock price is justified.<BR><BR>In summary, while the year-on-year growth figures are positive, the sequential declines and high valuation suggest that the latest results may not be viewed favorably by investors. The company faces challenges that could impact its future performance, making it a cautious outlook for potential investors.

Should I buy, sell or hold Max Healthcare Institute Ltd?

Why is Max Healthcare Institute Ltd falling/rising?

As of 17-Mar, Max Healthcare Institute Ltd's stock price is rising to 976.25, following a trend reversal after four days of decline and increased investor participation. However, it remains below its moving averages and close to its 52-week low, despite strong long-term growth metrics and high institutional holdings.

As of 17-Mar, Max Healthcare Institute Ltd's stock price is rising, currently at 976.25, reflecting an increase of 6.2 (0.64%). This upward movement follows a trend reversal after four consecutive days of decline. The stock's performance today is in line with its sector, and there has been a notable increase in investor participation, with delivery volume rising by 138.25% against the 5-day average. <BR><BR>Despite the recent rise, the stock is still trading below its moving averages across various time frames, indicating potential underlying weaknesses. Additionally, it is close to its 52-week low, being only 4.35% away from Rs 933.8. <BR><BR>On a broader scale, while the stock has experienced a decline of 6.57% year-to-date, it has shown significant growth over the past three years, with a return of 112.14%. The company boasts a low debt-to-equity ratio of 0.08 times and strong long-term growth metrics, including a 33.07% annual increase in net sales and a 76.96% rise in operating profit. High institutional holdings at 71.76% suggest confidence from larger investors, who typically have more resources to analyze company fundamentals.<BR><BR>In summary, the stock's current rise can be attributed to a trend reversal after a period of decline, increased investor participation, and the company's solid fundamentals, despite some concerns regarding its recent performance and valuation compared to peers.

Why is Max Healthcare Institute Ltd falling/rising?

As of 18-Mar, Max Healthcare Institute Ltd's stock price has risen slightly to 978.95, but it underperforms its sector and shows weakness across various moving averages. Despite a recent uptick, the stock has declined over the past week and month, indicating ongoing challenges, though the company maintains a low debt-to-equity ratio and strong long-term growth.

As of 18-Mar, Max Healthcare Institute Ltd is experiencing a slight rise in its stock price, currently at 978.95, with a change of 2.7 (0.28%) upward. This increase follows a two-day consecutive gain, where the stock has risen by 0.92%. However, it is important to note that the stock has underperformed its sector by 1.02% today and is trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a general trend of weakness.<BR><BR>Despite the recent uptick, the stock has shown a negative performance over the past week and month, with declines of 5.12% and 9.87%, respectively. Additionally, the stock is currently 4.61% away from its 52-week low, which suggests that it is still under pressure. The delivery volume has also decreased by 8.51% against the 5-day average, reflecting falling investor participation.<BR><BR>On a more positive note, the company has a low debt-to-equity ratio of 0.08 times, indicating financial stability, and has demonstrated healthy long-term growth with net sales increasing at an annual rate of 33.07% and operating profit at 76.96%. Furthermore, high institutional holdings at 71.76% suggest that knowledgeable investors are backing the company.<BR><BR>In summary, while Max Healthcare Institute Ltd is currently seeing a slight rise in its stock price, the overall performance metrics indicate ongoing challenges, including underperformance relative to its sector and declining investor participation.

Why is Max Healthcare Institute Ltd falling/rising?

As of 19-Mar, Max Healthcare Institute Ltd's stock price is at 956.45, reflecting a 2.35% decrease and indicating a bearish trend as it trades below all key moving averages. The stock has underperformed against the Sensex, with significant declines over various time frames, and declining investor participation suggests ongoing negative sentiment.

As of 19-Mar, Max Healthcare Institute Ltd's stock price is falling, currently at 956.45, which reflects a decrease of 23.05 or 2.35%. The stock has experienced a trend reversal, having fallen after two consecutive days of gains. Additionally, it is trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>In terms of performance, the stock has underperformed compared to the benchmark Sensex, with a 1-week decline of 6.26% against the Sensex's 2.40% drop, and a 1-month decline of 11.53% compared to the Sensex's 10.05%. Year-to-date, the stock is down 8.46%, while the Sensex has decreased by 12.92%. Over the past year, Max Healthcare has generated a return of -11.85%, significantly underperforming the broader market, which has seen a return of 1.22%.<BR><BR>Investor participation appears to be declining, as evidenced by a 48.5% drop in delivery volume compared to the 5-day average. Furthermore, the stock is close to its 52-week low, just 2.37% away from Rs 933.8. The Hospital & Healthcare Services sector has also seen a decline of 2.8%, contributing to the negative sentiment surrounding the stock.<BR><BR>Despite some positive factors, such as a low debt-to-equity ratio and healthy long-term growth in net sales and operating profit, the stock's current performance and market conditions suggest a bearish outlook.

Why is Max Healthcare Institute Ltd falling/rising?

As of 20-Mar, Max Healthcare Institute Ltd's stock price is currently at Rs 964.75, reflecting a 1.22% increase today. Despite a 15.07% decline over the past year, recent positive performance is driven by strong growth metrics and increasing investor interest.

As of 20-Mar, Max Healthcare Institute Ltd's stock price is rising, currently at Rs 964.75, reflecting an increase of Rs 11.65 or 1.22%. This upward movement is notable as the stock has outperformed its sector by 0.66% today and reached an intraday high of Rs 973.8, which is a 2.17% increase. <BR><BR>Despite the positive performance today, the stock has faced challenges over the longer term, with a decline of 15.07% over the past year, indicating that it has underperformed compared to the broader market, which has generated returns of 0.76% in the same period. However, the stock's current rise can be attributed to several factors, including a healthy long-term growth outlook, as evidenced by a significant annual growth rate in net sales of 33.07% and operating profit growth of 76.96%. Additionally, the company has a low debt-to-equity ratio of 0.08 times, which is favorable for investors.<BR><BR>Investor participation appears to be increasing, with a delivery volume of 35.89 lacs on 19 March, up by 0.13% against the 5-day average, suggesting growing interest in the stock. Furthermore, the stock's liquidity is adequate for trading, with a market capitalization of Rs 93,076 crore, making it the second largest company in its sector.<BR><BR>In summary, while Max Healthcare Institute Ltd has experienced significant declines over the past year, its recent price increase can be attributed to positive short-term performance, strong growth metrics, and rising investor participation.

Why is Max Healthcare Institute Ltd falling/rising?

As of 23-Mar, Max Healthcare Institute Ltd's stock price is Rs 951.25, down 1.4%, and has underperformed the market with a one-year return of -18.52%. The stock is trading below its moving averages and near its 52-week low, indicating a bearish trend and reduced investor interest.

As of 23-Mar, Max Healthcare Institute Ltd's stock price is falling, currently at Rs 951.25, which reflects a decrease of Rs 13.5 or 1.4%. The stock has underperformed compared to the broader market, with a one-year return of -18.52%, significantly worse than the BSE500's decline of -3.31%. <BR><BR>In the short term, the stock is trading lower than its moving averages across various periods, indicating a bearish trend. Additionally, the stock is close to its 52-week low, just 1.83% away from Rs 933.8. The performance today shows that it touched an intraday low of Rs 937.3, down 2.85%. <BR><BR>Investor participation has also declined, with delivery volume dropping by 15.89% compared to the five-day average, suggesting reduced interest from investors. The sector itself, Hospital & Healthcare Services, has seen a decline of 2.37%, which may be impacting Max Healthcare's performance as well.<BR><BR>Despite some positive factors, such as a low debt-to-equity ratio and healthy long-term growth in net sales and operating profit, the stock's valuation appears expensive compared to its peers. The company has also reported flat results recently, with a high enterprise value to capital employed ratio, which may deter potential investors. Overall, these factors contribute to the stock's current downward movement.

Why is Max Healthcare Institute Ltd falling/rising?

As of 24-Mar, Max Healthcare Institute Ltd's stock price is rising to Rs 969.15, reflecting a 1.34% increase today. This rise is driven by positive sector trends and short-term bullish sentiment, although the stock has underperformed over the past month and year, with decreased investor participation indicating potential concerns.

As of 24-Mar, Max Healthcare Institute Ltd's stock price is rising, currently at Rs 969.15, reflecting an increase of Rs 12.8 or 1.34%. This upward movement occurs despite the stock's recent underperformance, as it has fallen by 10.82% over the past month and 15.46% over the last year. However, today, the stock has shown some resilience, touching an intraday high of Rs 983, which is a 2.79% increase from its previous levels.<BR><BR>The rise in stock price today can be attributed to a broader positive trend in the Hospital & Healthcare Services sector, which has gained by 2.48%. Additionally, the stock is currently higher than its 5-day moving averages, indicating a short-term bullish sentiment. Despite this, it is important to note that the stock is still close to its 52-week low, being only 3.65% away from Rs 933.8.<BR><BR>Investor participation has decreased significantly, with delivery volume falling by 44.13% compared to the 5-day average, which may indicate a lack of confidence among retail investors. However, the company maintains a low debt-to-equity ratio of 0.08 times and has demonstrated healthy long-term growth, with net sales increasing at an annual rate of 33.07% and operating profit growing at 76.96%. Furthermore, high institutional holdings at 71.76% suggest that more sophisticated investors are backing the company, which could provide some support for the stock price.<BR><BR>In summary, while Max Healthcare Institute Ltd has faced significant declines over longer periods, the current rise in its stock price can be linked to sector performance and short-term trading dynamics, despite underlying concerns about its overall performance and investor sentiment.

Why is Max Healthcare Institute Ltd falling/rising?

As of 25-Mar, Max Healthcare Institute Ltd's stock price is at Rs 991.60, reflecting a 2.25% increase. Despite recent gains, the stock has declined over the past month and year, but strong fundamentals and high institutional holdings support investor confidence.

As of 25-Mar, Max Healthcare Institute Ltd's stock price is rising, currently at Rs 991.60, reflecting an increase of Rs 21.8 or 2.25%. This upward movement is supported by a performance that has been inline with the sector, which has gained by 2.44%. The stock has experienced consecutive gains over the last two days, accumulating a total return of 3.69% during this period. Additionally, the stock reached an intraday high of Rs 992.45.<BR><BR>Despite a generally negative trend over the past month and year, where the stock has seen declines of 8.97% and 15.39% respectively, its performance over the last week has been positive, with a return of 1.24% compared to a decline in the benchmark Sensex of 1.87%. The company's strong fundamentals, including a low debt-to-equity ratio of 0.08 and significant annual sales growth of 33.07%, contribute to investor confidence. Furthermore, high institutional holdings at 71.76% indicate that knowledgeable investors are backing the stock, which can positively influence its price.<BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume falling by 44.51% against the 5-day average. This could suggest caution among retail investors despite the recent price increase. Overall, the combination of short-term gains, sector performance, and strong institutional backing appears to be driving the stock's rise at this time.

Which are the latest news on Max Healthcare?